![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 31/506 | (2006.01) |
A61P 35/00 | (2006.01) | ||
A61K 9/00 | (2006.01) | ||
C07D 239/69 | (2006.01) |
(11) | Number of the document | 2501384 |
(13) | Kind of document | T |
(96) | European patent application number | 10781781.9 |
Date of filing the European patent application | 2010-11-17 | |
(97) | Date of publication of the European application | 2012-09-26 |
(45) | Date of publication and mention of the grant of the patent | 2016-02-17 |
(46) | Date of publication of the claims translation | 2016-05-10 |
(86) | Number | PCT/US2010/056926 |
Date | 2010-11-17 |
(87) | Number | WO 2011/062927 |
Date | 2011-05-26 |
(30) | Number | Date | Country code |
261812 P | 2009-11-17 | US |
(72) |
GALLAGHER, Neil, CH
YIN, Ophelia, US
|
(73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Proliferacinių sutrikimų ir kitų patologinių būklių, medijuojamų Bcr-Abl, c-Kit, DDR1, DDR2 arba PDGF-R kinazės aktyvumo, gydymo būdas |
METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY |
Payment date | Validity (years) | Amount | |
2024-10-21 | 15 | 289.00 EUR |
2025-11-17 |